| Literature DB >> 26013357 |
Ben P Hung1,2, Daphne L Hutton1,2, Kristen L Kozielski1,2, Corey J Bishop1,2, Bilal Naved3, Jordan J Green1,2, Arnold I Caplan4, Jeffrey M Gimble5, Amir H Dorafshar6, Warren L Grayson1,2,7.
Abstract
Tissue engineering using mesenchymal stem cells (MSCs) holds great promise for regenerating critically sized bone defects. While the bone marrow-derived MSC is the most widely studied stromal/stem cell type for this application, its rarity within bone marrow and painful isolation procedure have motivated investigation of alternative cell sources. Adipose-derived stromal/stem cells (ASCs) are more abundant and more easily procured; furthermore, they also possess robust osteogenic potency. While these two cell types are widely considered very similar, there is a growing appreciation of possible innate differences in their biology and response to growth factors. In particular, reports indicate that their osteogenic response to platelet-derived growth factor BB (PDGF-BB) is markedly different: MSCs responded negatively or not at all to PDGF-BB while ASCs exhibited enhanced mineralization in response to physiological concentrations of PDGF-BB. In this study, we directly tested whether a fundamental difference existed between the osteogenic responses of MSCs and ASCs to PDGF-BB. MSCs and ASCs cultured under identical osteogenic conditions responded disparately to 20 ng/ml of PDGF-BB: MSCs exhibited no difference in mineralization while ASCs produced more calcium per cell. siRNA-mediated knockdown of PDGFRβ within ASCs abolished their ability to respond to PDGF-BB. Gene expression was also different; MSCs generally downregulated and ASCs generally upregulated osteogenic genes in response to PDGF-BB. ASCs transduced to produce PDGF-BB resulted in more regenerated bone within a critically sized murine calvarial defect compared to control ASCs, indicating PDGF-BB used specifically in conjunction with ASCs might enhance tissue engineering approaches for bone regeneration.Entities:
Keywords: Bone; Platelet-derived growth factor; Stem cells; Tissue engineering
Mesh:
Substances:
Year: 2015 PMID: 26013357 PMCID: PMC4549224 DOI: 10.1002/stem.2060
Source DB: PubMed Journal: Stem Cells ISSN: 1066-5099 Impact factor: 6.277